ACMG 

Dr. Lipkin is an internationally recognized clinical geneticist physician scientist and expert in genetic disease, particularly hereditary cancer predisposition. Before joining Ambry, Dr. Lipkin served as the Gladys and Roland Harriman Professor of Medicine and Vice Chair for Research, Department of Medicine at Weill Cornell Medicine and he also directed the Adult and Cancer Genetics Clinic and the Program in Mendelian Genetics. He has guided advancements in genetic medicine through key advisory roles for the US Food and Drug Administration on the Molecular and Clinical Genetics Panel, including the Exact Cologuard test.

In her role as a Clinical Strategy Manager for Research and Collaborations, Carrie works to aligning our research strategies with unmet clinical needs and to ensure that our findings are amplified to reach the right audience. In particular, Carrie is interested in exploring proactive steps labs can take to promote genomic test equity and improve access for all patient populations.

Stephany is a Principal Clinical Genomic Scientist leading Ambry’s Patient for Life program. The Patient for Life team continuously reviews previously tested patients for any updated information that could impact results and patient care. Come meet Stephany to learn more about how Ambry’s exciting Patient for Life program will benefit your patients for the rest of their lives

As Director of Bioinformatics, Matthew Schultz, PhD, focuses on developing computational and statistical methods that transform large-scale genomic data into meaningful clinical insights. He is particularly dedicated to leveraging pangenomes to address the technical challenges of genomic equity, working to build robust bioinformatics solutions that overcome bias and ensure accurate, actionable results for all patient populations

Matthew Schultz, PhD: As Director of Bioinformatics, Matthew Schultz, PhD, focuses on developing computational and statistical methods that transform large-scale genomic data into meaningful clinical insights. He is particularly dedicated to leveraging pangenomes to address the technical challenges of genomic equity, working to build robust bioinformatics solutions that overcome bias and ensure accurate, actionable results for all patient populations.